EMD Serono, the U.S. division of Merck KGaA, is parting ways with an undisclosed number of employees. The layoffs will affect research staff at the company’s offices in Durham, North Carolina.
All entries for: Neurological Diseases
November 18, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck is letting go of 204 employees from its Rahway, New Jersey location, continuing its aggressive layoff spree in recent months.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 17, 2025
Bristol Myers Squibb
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb has announced another round of layoffs, affecting 110 employees at the Lawrence Township site.
Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 13, 2025
Trevi Therapeutics, Inc.
Neutral Outlook
New Haven, CT
1-50 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage.
Disease Area: Multiple, Neurological Diseases, Respiratory
Drug Type: Small Molecule
November 12, 2025
Acurx Pharmaceuticals, Inc.
Neutral Outlook
Waltham, MA
201-500 employees
In August 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law. The IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the drug product’s price increases faster than the rate of inflation.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
November 12, 2025
Zenas Biopharma
Neutral Outlook
Waltham, MA
51-200 employees
Notably, the Inflation Reduction Act of 2022 (the “IRA”) includes a number of healthcare reform provisions, which have varying implementation dates. The IRA extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025
Disease Area: Chronic Disease, Immune Diseases, Neurological Diseases
Drug Type: Biologic
November 12, 2025
Kalaris Therapeutics
Negative Outlook
Palo Alto, CA
1-50 employees
Further, with the passage of the Inflation Reduction Act (the “IRA”) in August 2022, Congress extended the expansion of ACA premium tax credits through 2025. These and other laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products or product candidates for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
November 6, 2025
Neumora Therapeutics, Inc.
Neutral Outlook
Waltham, Massachusetts,
51-200 employees
On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the “IRA”) into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. It is unclear how other healthcare reform measures of the Trump administration or other efforts, if any, to challenge, repeal or replace the ACA, will impact our business.
Disease Area: Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
November 6, 2025
Collegium Pharmaceutical, Inc.
Negative Outlook
Stoughton, MA
201-500 employees
We expect that additional changes to the Affordable Care Act, the Medicare and Medicaid programs, changes in the Inflation Reduction Act of 2022 that allow the federal government to directly negotiate drug prices, and changes stemming from other healthcare reform measures, including any new regulatory measures proposed or implemented by the Trump Administration, especially with regard to healthcare access and cost, as well as other legislation in individual states, could have a material adverse effect on the healthcare industry.
Disease Area: Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule